MedTrace Logo

A Clinical Study of Gecacitinib Combined With Pegylated Interferon in Patients With PV

NCT07445893 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-06-24

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the efficacy and safety of Gecacitinib in combination with pegylated interferon for the treatment of polycythemia vera (PV).The main question it aims to answer is:

Can PV patients achieve hematological remission after receiving the combination therapy?

Participants will:

Receive combination treatment with Gecacitinib Hydrochloride Tablets and pegylated interferon for 24 weeks Visit the hospital regularly for examinations and follow-up assessments

Conditions

  • Polycythemia Vera (PV)

Interventions

DRUG

Gecacitinib Hydrochloride Tablets；Pegylated interferon alfa-2b

Gecacitinib Hydrochloride Tablets: 100 mg twice daily (BID), orally, on an empty stomach. Pegylated interferon alfa-2b: 90 μg once weekly, subcutaneous injection in the abdomen or thigh.

Sponsors & Collaborators

  • Duan Minghui

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-02
Primary Completion
2026-12-30
Completion
2028-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07445893 on ClinicalTrials.gov